5.18.2017

Southern EU states present unified front in drug talks

›
Folks an article on the intensified pricing collaboration activities among European countries. This has been a long debate for years but it...
10.04.2016

The Future of Health Economics - new book availabe soon

›
Dear All, Olivier, the "work horse" ;) finally managed to get all the chapters back from the various authors and the book goes...
8.18.2016

IQWIG not bullish on EMAs adaptive pathways pilot

›
Hi All, just saw an interesting post ( https://www.iqwig.de/en/press/press-releases/press-releases/adaptive-pathways-ema-still-leaves-open...
4.27.2016

Drug prices: Tweaking the formula

›
Financial Times By Andrew Ward April 25, 2016   What is the value of a human life? It is one of the most fraught questions in pub...
11.22.2015

Patient Access positions with Baxalta

›
Dear Readers, I am currently building my access team in EMEA and have a few positions open. I am looking for a patient access lead oncolog...
7.23.2015

England NHS cancer drug fund to be handed over to NICE?

›
Dear All, Some interesting developments on the Cancer Drug Fund have been announced today. Cheers Ulf
6.18.2015

Market Access in Germany and AMNOG reform needs

›
Dear All, hope you are getting ready for the summer.. just came across an interesting post on the GKV Spitzenverband website . A latest st...
3.21.2015

The value discussion

›
Dear All, first of all apologies for the quite time lately, been busy with various projects. Seeing the article from Ed it reminded me of...
10.14.2014

Potential "Pay if you clear" access scheme in Scotland

›
Dear All, just saw this on BBC Now if that scheme materializes it truly deserves to be called an innovative one .. Cheers Ulf
7.24.2014

Jobs and interviewing in Market Access, Health Economics and Pricing

›
Dear All, a little post from the beach, I trust most of the readers enjoying their well deserved summer vacation. By popular demand in the...
5.26.2014

Guidelines for payment by results in Catalunya

›
Dear All, CatSalut has published a first version of guidelines for the implementation of payment by results schemes for pharmaceuticals. ...
5.08.2014

No linear association between drug prices and perceived benefit criticises US cancer expert...

›
Dear all, pricing of cancer drugs and now also hepatitis C has steered another debate among US payers and physicians about drug prices. Se...
2.18.2014

Germany becoming the "wild card" in drug pricing

›
Dear Readers, just saw this in the news (see link below). Germany is thinking of issuing a new law that the so far confidential price disc...
1 comment:
12.04.2013

Critique on lower NICE threshold research

›
Hi everyone, sitting here on my desk with a typical December cold, I came across this critique from the OHE of something that gives me ev...
2 comments:
11.21.2013

UK VBP - paddling back big time ?

›
Dear All, it took some time for the UK government to come out with something on the VBP debate. Now the first details of the new "dea...